United States

People: Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

28 Mar 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Paul, Steven 

Dr. Steven M. Paul, M.D., is Independent Director of Alnylam Pharmaceuticals, Inc. Dr. Paul has served as the President, Chief Executive Officer and a director of Voyager Therapeutics, Inc., a biotechnology company, since September 2014. Dr. Paul was the founding director of the Appel Alzheimer’s Disease Research Institute, and is a Professor of Neurology (Neuroscience), Psychiatry and Pharmacology at Weill Cornell Medical College of Cornell University, and a Venture Partner at Third Rock Ventures, a healthcare venture firm. Dr. Paul served for 17 years at Eli Lilly and Company, a pharmaceutical company, most recently as the Executive Vice President for Science and Technology and President of the Lilly Research Laboratories, a division of Eli Lilly and Company, from July 2003 to his retirement in February 2010. He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science. Prior to joining Lilly, Dr. Paul served in several senior roles at the National Institute of Mental Health, including serving as the Scientific Director of the Intramural Research Program. Dr. Paul also serves as a director of Voyager Therapeutics, Inc. and SAGE Therapeutics, Inc., and formerly served as a director of the Sigma-Aldrich Corporation (which was acquired by Merck KGaA).

Basic Compensation

Total Annual Compensation, USD 65,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 453,713
Fiscal Year Total, USD 518,713

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Bonney


Barry Greene


John Maraganore


Michael Mason


Yvonne Greenstreet


Akshay Vaishnaw

As Of  30 Dec 2016